Novel drug approval by the FDA: Ekterly (Sebetralstat), oral plasma kallikrein inhibitor for treating acute attacks of hereditary angioedema.

Hereditary angioedema (HAE) remains a challenging, potentially life-threatening disorder driven by dysregulated plasma kallikrein activity and excessive bradykinin generation. Despite major therapeutic advances, most available treatments for acute attacks rely on injectable or intravenous agents that impose barriers to timely administration, particularly in low-resource or emergency-limited settings. The recent FDA approval of Ekterly (sebetralstat), the first orally administered plasma kallikrein inhibitor for acute HAE attacks in patients aged 12 years and older, represents a landmark shift in the management of this rare disorder. In this editorial, we highlight the scientific rationale behind sebetralstat, summarize key findings from the KONFIDENT clinical trial, and evaluate its safety, efficacy, and clinical applicability. Ekterly demonstrated a significantly faster onset of symptom relief, earlier reduction in attack severity, and more rapid attack resolution compared with placebo, marking a meaningful improvement over existing therapies. Its oral administration represents a significant therapeutic advancement, allowing patients to manage acute attacks promptly and independently without reliance on clinical facilities. This is particularly advantageous in settings with limited access to intravenous therapy, cold-chain storage, or timely emergency care. The novelty of our work lies in synthesizing emerging mechanistic insights, regulatory developments, real-world applicability, and clinical trial performance into a unified evaluation of the first oral short-term prophylactic and on-demand kallikrein inhibitor for HAE. Through a detailed appraisal of its therapeutic efficacy, safety profile, and pharmacologic constraints -including clinically relevant interactions with CYP3A4 modulators and the lack of evidence in pregnant patients or those with hepatic impairment ,this editorial emphasizes Ekterly's emerging role as an important and potentially transformative addition to HAE management.The approval of sebetralstat signals a new era of convenient, rapid-acting, accessible treatment for HAE, with the potential to reduce emergency visits, enhance patient autonomy, and improve quality of life. Continued surveillance, long-term safety studies, and global access initiatives will be essential to maximize its public-health impact and ensure equitable availability of this breakthrough oral therapy.